Dachaigh › Dermatitis Atopach (Eczema) › Oregon
Sgrùdaidhean clionaigeach Dermatitis Atopach (Eczema) ann an Oregon
Tha 6 sgrùdaidhean airson Dermatitis Atopach (Eczema) a’ lorg phàirtichean aig làraichean ann an Oregon.
Bailtean ann an Oregon
Teacsa sgrùdaidh oifigeil (Beurla)
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Portland
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07003425A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
A’ fastadhÌre 2
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 12 Lùna 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Oregon Health and Science University /ID# 266483, Portland
A’ fastadhÌre 3
Aoisean 2 gu 11 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Portland
A’ fastadhÌre 3
6 Months – 11 Years · Gach gnè · Air ùrachadh 7 Iuch 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Oregon Health and Science University /ID# 263736, Portland
A’ fastadhÌre 3
Aoisean 18 gu 63 · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT06389136Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7073, Gresham
A’ fastadhSgrùdadh amharc
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT06988605Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.